CN115968375A - SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂 - Google Patents

SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂 Download PDF

Info

Publication number
CN115968375A
CN115968375A CN202180038369.XA CN202180038369A CN115968375A CN 115968375 A CN115968375 A CN 115968375A CN 202180038369 A CN202180038369 A CN 202180038369A CN 115968375 A CN115968375 A CN 115968375A
Authority
CN
China
Prior art keywords
patient
cannabidiol
cells
interferon
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038369.XA
Other languages
English (en)
Chinese (zh)
Inventor
施里玛·麦钱特
马尼特·帕特尔
罗宾·伊莱恩·邓肯
维沙尔·阿南特·贾达夫
玛丽亚·费尔南达·德·安德拉德·费尔南德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akira Pharmaceuticals
Original Assignee
Akira Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akira Pharmaceuticals filed Critical Akira Pharmaceuticals
Publication of CN115968375A publication Critical patent/CN115968375A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180038369.XA 2020-03-29 2021-03-30 SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂 Pending CN115968375A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN202021013770 2020-03-29
IN202021013770 2020-03-29
IN202021030633 2020-07-18
IN202021030633 2020-07-18
IN202021054151 2020-12-12
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (1)

Publication Number Publication Date
CN115968375A true CN115968375A (zh) 2023-04-14

Family

ID=77927896

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038369.XA Pending CN115968375A (zh) 2020-03-29 2021-03-30 SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂

Country Status (9)

Country Link
US (1) US20240226120A1 (https=)
EP (1) EP4126913A4 (https=)
JP (1) JP2023528561A (https=)
CN (1) CN115968375A (https=)
AU (1) AU2021247269A1 (https=)
BR (1) BR112022019649A2 (https=)
IL (1) IL296892A (https=)
MX (1) MX2022012165A (https=)
WO (1) WO2021199078A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途
CN115531315B (zh) * 2022-12-05 2023-04-07 上海惠盾因泰生物科技有限公司 重组人干扰素λ1鼻喷雾剂及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111686095A (zh) * 2020-07-24 2020-09-22 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
WO2017011785A1 (en) * 2015-07-15 2017-01-19 National Concessions Group Inc. Topical antiviral formulations and methods of using the same
WO2020257588A1 (en) * 2019-06-20 2020-12-24 Shaman Naturals, Llc Compositions for preventing and treating viral infections
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途
US11338010B2 (en) * 2020-03-30 2022-05-24 Suzhou Kintor Pharmaceuticals, Inc. Systems, methods, and kits for diagnostics and treatment of viral respiratory infection
US20230181484A1 (en) * 2020-05-11 2023-06-15 Add Advanced Drug Delivery Technologies Ltd. Uses and Formulations of Cannabinoids
US20230338396A1 (en) * 2020-05-14 2023-10-26 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111686095A (zh) * 2020-07-24 2020-09-22 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIUSEPPE ESPOSITO等: "The potential of cannabidiol in the COVID-19 pandemic", 《BRITISH JOURNAL OF PHARMACOLOGY》, 10 June 2020 (2020-06-10), pages 4967 *
LONG CHI NGUYEN等: "Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response", 《BIORXIV》, 10 March 2021 (2021-03-10) *

Also Published As

Publication number Publication date
BR112022019649A2 (pt) 2022-12-27
WO2021199078A3 (en) 2021-12-09
US20240226120A1 (en) 2024-07-11
WO2021199078A2 (en) 2021-10-07
MX2022012165A (es) 2023-01-24
JP2023528561A (ja) 2023-07-05
AU2021247269A1 (en) 2022-12-01
EP4126913A4 (en) 2024-09-18
IL296892A (en) 2022-12-01
EP4126913A2 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
US10987329B1 (en) Combination therapy for coronavirus infections including the novel corona virus (COVID-19)
CN115968375A (zh) SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂
US20210361688A1 (en) System, method and use of a certain medication for reducing viral replication in the airways mucosae
US20240024337A1 (en) Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
Guo et al. Pyroptosis in glioma: current management and future application
US11883376B2 (en) Viral infection treatment with 5-aminolevulinic acid
US20230321126A1 (en) Micronutrient combination to inhibit coronavirus cell infection
CN113679726A (zh) 丹参提取物和醌类化合物在抗冠状病毒中的应用
KR20200131784A (ko) 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
JP2023516284A (ja) カンナビジオールの組成物および治療的使用
CA3179317A1 (en) Methods for the prophylaxis and treatment of covid and covid-19
WO2022257936A1 (en) Method and composition for preventing and treating covid-19 and long covid
US12544388B2 (en) Compound for treating and/or preventing diseases caused by coronavirus and use thereof
Elkholy et al. Ivermectin: a closer look at a potential remedy
US20230381141A1 (en) Conjoint therapies for treating viral infections
Cursaro et al. A Focus on Natural Autophagy Modulators as Potential Host‐Directed Weapons Against Emerging and Re‐Emerging Viruses
Chih-Ching et al. Green tea polyphenol catechins inhibit coronavirus replication and potentiate the adaptive immunity and autophagy-dependent protective mechanism to improve acute lung injury in mice
RU2804307C1 (ru) Филлирин и его производные для подавления белка 3clpro и борьбы с вирусом covid-19
Kandimalla et al. Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2
Feferbaum-Leite et al. Insights into enterovirus a-71 antiviral development: from natural sources to synthetic nanoparticles
ARISOY et al. Potential Treatment Approaches to SARS-CoV-2 and Evaluation of Drug Carrier Systems in Treatment
CN108888628A (zh) 一种人参皂苷GRh2在制备抗弓形虫复方制剂中的应用及其药物
US20230391837A1 (en) Methods of treating, ameliorating, and/or preventing covid-19 infection and related inflammation
Rugeles et al. Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review Paula Andrea Velásquez1, 2, Juan C Hernandez 1, 2, Elkin Galeano3, Jaime Hincapié-García4
WO2016142568A1 (es) Análogos de ferruginol como agentes antivirales

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination